- New report upgrades HeartBeam to buy, raises 12-month price target to $4, citing regulatory progress and company’s transition toward commercialization.
- Joseph Gunnar characterized the FDA clearance of HeartBeam’s 12-lead ECG synthesis software for arrhythmia assessment as a “critical regulatory milestone.”
- The research report underscores the company’s targeted go-to-market strategy.
Equity research reports often serve as important barometers of shifting sentiment, offering investors detailed analysis of a company’s strategy, risks and growth potential. In a new research note, Joseph Gunnar & Co. upgraded HeartBeam (NASDAQ: BEAT) from Hold to Buy and raised its 12-month price target to $4 from $1, citing regulatory progress and the company’s transition toward commercialization. A medical tech company, HeartBeam will introduce its FDA-cleared cable-free, synthesized 12-lead ECG system designed to deliver clinical-grade cardiac insights for arrhythmia assessment in a portable format, and the upgrade reflects growing confidence in the company’s commercial launch strategy and long-term opportunity.
“We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection,” the February 2026 report states. The report highlights a significant turning point for the company following FDA clearance of its 12-lead ECG synthesis…
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN